Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “breast cancer”

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive Not Recruiting
NCT04704661Phase 1Updated Sep 4, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Breast Carcinoma · Advanced Colon Carcinoma · Advanced Colorectal Carcinoma · Advanced Endometrial Carcinoma
United States
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid TumorsRecruiting
NCT07661641Phase 1Updated Sep 4, 2026
Sponsor: Alpha-9 Oncology USA Inc.
Breast Cancer · Prostate Cancer · Colorectal Cancer · GRPR-positive Solid Tumors
Australia
Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast CancerRecruiting
NCT03177902N/AUpdated Sep 4, 2026
Sponsor: The First Affiliated Hospital of Bengbu Medical University
Breast Cancer Female · Thyroid Gland
China
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive Not Recruiting
NCT01366144Phase 1Updated Sep 4, 2026
Sponsor: National Cancer Institute (NCI)
Breast Carcinoma · Carcinoma of Unknown Primary · Endometrial Carcinoma · Esophageal Carcinoma
United States
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsRecruiting
NCT07361562Phase 1Updated Sep 4, 2026
Sponsor: Cogent Biosciences, Inc.
Advanced Solid Tumor, Adult · ERBB2 Altered Breast Cancer · ERBB2 Gene Amplification · HER2 Overexpression
United States
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyTerminated
NCT02927249Phase 3Updated Sep 4, 2026
Sponsor: Alliance for Clinical Trials in Oncology
Node Positive HER2 Negative Breast Cancer
United States, Canada, Guam, Puerto Rico
A Study of LY4257496 in Participants With Cancer (OMNIRAY)Recruiting
NCT07114601Phase 1Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Breast Neoplasms · Colorectal Neoplasms · Prostate Neoplasm · Endometrial Neoplasms
United States, Canada, China, France, Germany +2 more
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive Not Recruiting
NCT02208375Phase 1Updated Sep 4, 2026
Sponsor: M.D. Anderson Cancer Center
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Endometrial Adenocarcinoma · Estrogen Receptor Negative
United States
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid TumorsRecruiting
NCT07459283EARLY_Phase 1Updated Sep 4, 2026
Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.
Maligant Solid Tumor · Head & Neck Cancer · Thyroid Cancer · Lung Cancer - Non Small Cell Squamous
China
Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before SurgeryRecruiting
NCT05327608NAUpdated Sep 3, 2026
Sponsor: Thomas Jefferson University
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Invasive Breast Carcinoma
United States
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRecruiting
NCT06982521Phase 3Updated Sep 3, 2026
Sponsor: Relay Therapeutics, Inc.
PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor · Breast Cancer
United States, Argentina, Australia, Austria, Belgium +19 more
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast CancerRecruiting
NCT06635980Phase 2Updated Sep 3, 2026
Sponsor: Mayo Clinic
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Breast Carcinoma
United States
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsActive Not Recruiting
NCT06271837Phase 2Updated Sep 3, 2026
Sponsor: AstraZeneca
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
China
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast CancersRecruiting
NCT05846789Phase 2Updated Sep 3, 2026
Sponsor: Kathy Miller
Metastatic Breast Cancer · Triple Negative Breast Cancer · Estrogen-receptor-low Breast Cancer · ER Positive, HER2 Negative Breast Cancer
United States
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruiting
NCT04886531Phase 2Updated Sep 3, 2026
Sponsor: Ruth O'Regan
Breast Cancer · HER2-positive Breast Cancer · ER Positive Breast Cancer · PR-Positive Breast Cancer
United States
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
Use of an Interactive 3D Tool During Consultation for Breast Reconstruction SurgeryActive Not Recruiting
NCT05025020NAUpdated Sep 3, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer
United States
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase InhibitorsRecruiting
NCT05590949N/AUpdated Sep 3, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer
United States
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic TherapyActive Not Recruiting
NCT06055881NAUpdated Sep 3, 2026
Sponsor: Mayo Clinic
Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Breast Cancer
United States
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Recruiting
NCT06760819Phase 2Updated Sep 3, 2026
Sponsor: Bayer
Advanced Solid Tumors · HER2 Mutation
United States, Australia, Canada, China, Denmark +6 more
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot Yet Recruiting
NCT07802626Phase 3Updated Sep 3, 2026
Sponsor: SWOG Cancer Research Network
HR Positive/HER-2 Negative Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruiting
NCT06790693Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Brazil, Canada +15 more
The Effect of Self-Management Interventions Among Patients With Breast Cancer Related-LymphedemaCompleted
NCT07803549NAUpdated Sep 3, 2026
Sponsor: Al-Zaytoonah University of Jordan
Breast Cancer (Locally Advanced or Metastatic) · Lymphedema Arm
Jordan
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive Not Recruiting
NCT04873362Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Australia, Austria, Belgium, Brazil +27 more
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast CancerNot Yet Recruiting
NCT07801898Phase 2Updated Sep 3, 2026
Sponsor: The Second Hospital of Anhui Medical University
Invasive Breast Cancer (Stage I-III)
China

Previous page Next page